SION Sionna Therapeutics, Inc. stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 13, 2026Sionna Therapeutics, Inc. (SION) closed at $3.33 (-2.92%) on Nov 13, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 32, RS Rating 5, -93.9% from its 52-week high, -91.9% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Why SION moved
From the StockSetups movers recaps that covered SION, newest first. A recap states what was known that day.
- Close+23.1%
On August 11, SION cratered roughly 92% after its lead cystic fibrosis drug, SION-719, failed a Phase 2a clinical trial and the company halted its development.
Top Stock Movers Today — August 12, 2026: Why RMCF, SMCX, NBIS, SION & SHAZ Surged →
Financials as of Wed, Sep 30, 2026 · quarterly.
SION technical analysis
Trend
SION is in a downtrend: price is below the 50-day, which is below the 200-day moving average. It closed 32.3% below the 50-day ($4.92) and 88.2% below the 200-day ($28.22). ADX(14) at 39 points to a strong, established trend. It meets 0 of 8 trend-template criteria.
Momentum
RSI(14) is 32, in the bearish half of its range. The MACD histogram is positive. Its RS Rating of 5 puts its weighted 12-month performance ahead of about 5% of the US market.
Volume and volatility
Volume on the latest session ran 0.6× its 20-day average. It trades about $3.3M a day on average. ATR(14) is $0.3620, 10.9% of price — its typical daily range. Bollinger Bands are in a squeeze (7 sessions) — volatility is compressed. Chaikin Money Flow (-0.10) shows distribution.
Key levels
The chart pattern's support is $3.37 and its resistance $5.23. The 52-week range is $3.19 to $54.97; price is 93.9% below the high and 4.4% above the low. The VWAP anchored at the 52-week high is $5.48, above price.
Performance
SION returned +1.5% (1 week), -18.4% (1 month), -43.6% (3 months), -91.7% (6 months), -90.9% (1 year), -91.9% (year to date).
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Pharmaceutical Preparations · Listed 2025 · 59 employees
Insider activity
SEC Form 4 transactions in SION · open-market 5 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-09-17 | Sell | 33.8K | $252K | 2026-09-17 | 2026-09-21 |
RA CAPITAL MANAGEMENT, L.P. Director · Common Stock · 2026-09-17 | Sell | 3.42M | $22M | 2026-09-17 | 2026-09-21 |
ORBIMED ADVISORS LLC Director · Common Stock · 2026-07-07 | Sell | 85.92K | $3.9M | 2026-07-07 | 2026-07-09 |
Thompson Peter A. Director · Common Stock · 2026-07-07 | Sell | 85.92K | $3.9M | 2026-07-07 | 2026-07-09 |
Fitzpatrick Jennifer Chief Legal Officer · Common Stock · 2026-07-06 | Exercise | 10.25K | $63K | 2026-07-06 | 2026-07-07 |
Fitzpatrick Jennifer Chief Legal Officer · Common Stock · 2026-07-06 | Sell | 10.25K | $447K | 2026-07-06 | 2026-07-07 |
Fitzpatrick Jennifer Chief Legal Officer · Non-Qualified Stock Option (right to buy) · 2026-07-06 | Exercise | 10.25K | — | 2026-07-06 | 2026-07-07 |
Booth Bruce Director · Non-Qualified Stock Option (right to buy) · 2026-06-17 | Grant | 17.34K | — | 2026-06-17 | 2026-06-18 |
Clancy Paul J Director · Non-Qualified Stock Option (right to buy) · 2026-06-17 | Grant | 17.34K | — | 2026-06-17 | 2026-06-18 |
Fleming Harold Edward Director · Non-Qualified Stock Option (right to buy) · 2026-06-17 | Grant | 17.34K | — | 2026-06-17 | 2026-06-18 |
SEC filings
EDGAR filings in SION · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.